Duchenne muscular dystrophy (DMD) is one of the most common and devastating childhood genetic disorders, affecting ...

EDO51, an investigational therapy for Duchenne muscular dystrophy (DMD), and is still ongoing in the United Kingdom.

Percheron Therapuetic's key trial for Duchenne muscular dystrophy has flopped, sending the shares into freefall ...

Sevasemten significantly reduced two markers of muscle damage in treated Becker muscular dystrophy patients in Phase 2 CANYON ...

The year is ending with a strong flow of clinical results, with Percheron Therapeutics due to release key trial data tomorrow ...